Sixth Circuit Affirms Steep Sentence in FDC Act Counterfeiting Case

Why It Matters

The ruling sets a precedent for harsh sentencing calculations in counterfeit drug cases, influencing both prosecutors and defense strategies across the pharmaceutical and legal sectors.

Key Takeaways

• Sixth Circuit upheld 90‑month sentence for counterfeit alprazolam.
• Fraud loss calculated using street price, totaling $32 million.
• Ten‑or‑more‑victim enhancement applied to street buyers and manufacturers.
• Risk‑of‑death enhancement affirmed despite lack of proven harm.
• Ruling guides future sentencing in drug‑counterfeiting cases.

Pulse Analysis

The surge in counterfeit pharmaceuticals has become a national security concern, prompting agencies like the DEA to launch operations such as "Operation Meltdown" to dismantle illicit online pharmacies. Under the Federal Food, Drug, and Cosmetic (FDC) Act, counterfeit drug offenses carry a ten‑year maximum, but sentencing ultimately hinges on the U.S. Sentencing Commission Guidelines, which factor in fraud loss, victim count, and public safety risks. The Sixth Circuit’s recent opinion provides a concrete illustration of how these abstract guidelines translate into real‑world penalties.

In Wala’s case, the appellate court endorsed a street‑value approach to fraud loss, multiplying the $2 price per counterfeit pill by roughly 16.1 million units to reach a $32 million figure. This methodology, traditionally reserved for controlled‑substance cases, was deemed appropriate because the ultimate victims were street‑level purchasers deceived into believing they were buying legitimate alprazolam. The court also affirmed two key enhancements: one for ten or more victims—including the original drug manufacturers—and another for the conscious risk of death or serious bodily injury, reflecting the inherent danger of unregulated benzodiazepine analogs.

The decision signals a tougher stance for future prosecutions, especially when counterfeit drugs circulate solely in illicit markets. Defense attorneys will likely contest fraud‑loss calculations and victim‑enhancement thresholds, while legitimate manufacturers may explore restitution avenues despite mixed precedent. Moreover, cases where counterfeit products infiltrate the lawful supply chain could trigger different guideline applications, underscoring the need for vigilant compliance programs and robust monitoring of the pharmaceutical distribution ecosystem.